瑞舒伐他汀钙片与蒲参胶囊降脂疗效比较  被引量:7

Rosuvastatin Calcium and Pusen capsule lipid-lowering curative effect more

在线阅读下载全文

作  者:邓庆梅[1,2] 

机构地区:[1]大庆龙南医院老年病科 [2]齐齐哈尔医学院第五附属医院老年病科,黑龙江大庆163453

出  处:《中国伤残医学》2011年第12期21-23,共3页Chinese Journal of Trauma and Disability Medicine

摘  要:目的:观察瑞舒伐他汀钙片与蒲参胶囊降脂效果差别。方法:将确诊的高血脂患者随机分为2组:瑞舒伐他汀组42例,每晚服瑞舒伐他汀钙10mg;蒲参胶囊,每次4粒,每日3次;疗程8周。比较2组降脂效果,同时观察治疗期间不良事件。结果:2组治疗前后血脂水平变化比较与同组治疗前相比,治疗后TC、TG、LDL-C均有明显下降(P<0.05),HDL—C明显升高(P<0.05)。2组治疗8周后总有效率比较,TC、LDL-C总有效率瑞舒伐他汀组优于蒲参胶囊组,TG总有效率蒲参胶囊组优于瑞舒伐他汀组,有明显差异(P<0.05);HDL—C总有效率2组无明显差异(P>0.05).治疗期间2组不良反应均轻微。结论:瑞舒伐他汀对TC,LDL-C降低优于蒲参胶囊,蒲参胶囊对于TG的降低疗效优于瑞舒伐他汀钙片。Objective:To observe Rosuvastatin Calcium and Pusen capsule lipid-lowering effect difference. Methods:Will be diagnosed high blood fat patients were randomly divided into two groups:Rosuvastatin Calcium group were 42 patients,Take Rosuvastatin Calcium 10 mg per night; Pusen capsule,Every time 4 grain, 3 times a day; Course of 8 weeks. Compare two sets of reduced fat effect, and observed during treatment adverse events. Results:Two groups before and after treatment change is lipid levels before treatment, compared with your group.After treatment, the TC, TG, LDL-C were significantly down(P0.05),H DL-C increased significantly (P0.05). Two groups of treatment after eight weeks, the total effective rate compared,TC, LDL-C total effective Rosuvastatin Calcium group was higher than the Pusen capsule group,TG total effective the Pusen capsule group was higher than Rosuvastatin Calcium group,and there is a distinct difference (P0.05). HDL-C total effective rate no difference between the two groups (P0.05). During treatment, two groups of adverse reactions are minimal.Conclusions:Rosuvastatin Calcium of TC, LDL-C reduce might be better than Pusen capsule,.Pusen capsule for the better therapeutic TG reduce Rosuvastatin Calcium.

关 键 词:瑞舒伐他汀钙片 蒲参胶囊 降脂 

分 类 号:R917[医药卫生—药物分析学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象